Latest Commercialisation News

Lindian Resources has executed a binding agreement to acquire full ownership of a rare earths processing facility in Kazakhstan, marking a strategic shift from concentrate production to higher-value Mixed Rare Earth Carbonate (MREC) output by late 2026.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Terragen Holdings’ biostimulant Great Land Plus® has been independently shown to increase maize silage yields by up to 12%, translating into an estimated $1,100 additional revenue per hectare and a potential 20-fold return on investment.

ABx Group’s maiden mixed rare earth carbonate from Tasmania’s Deep Leads resource has been confirmed radiologically safe by ANSTO, with a second, higher-grade sample expected soon. The development could open doors to key international customers and reduce regulatory complexities.

Metal Powder Works has partnered with CenterLine to develop Kirksite alloy powders for cold spray automotive tooling, targeting a USD 100-300 million market. This collaboration aims to enhance tooling repair speed and cost-efficiency in the automotive sector.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

Nanoveu Limited reported a dramatic revenue increase driven by its strategic acquisition of Embedded A.I. Systems, while losses widened as it invests heavily in semiconductor commercialisation. The company’s recent $7.5 million capital raise aims to fuel its next growth phase.

Eden Innovations Ltd reports a $1.43 million half-year profit, reversing prior losses thanks to a $4.45 million property sale and significant debt reduction, while advancing international commercialisation of its concrete and fuel technologies.

Osteopore Limited reported an 11% increase in revenue to $3.06 million for 2025, alongside a wider net loss of $3.72 million as it invests heavily in product development and regulatory compliance. The company also expanded its footprint with a new Singapore subsidiary.

Yojee Limited reported a 9% revenue increase driven by software activities, while net losses widened due to accelerated investment in its MOSAIC platform and joint venture costs. The company maintains a robust cash balance and has strengthened its leadership ahead of a mid-2026 commercial launch.

ClearVue Technologies reported a 9% reduced half-year loss of $5.25 million, while pushing forward with significant advancements in its solar glass technology and expanding global licensing partnerships.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.